Theravance Biopharma, Inc. Excess Tax Benefit from Share-based Compensation, Financing Activities
Theravance Biopharma, Inc. (TBPH) reported Excess Tax Benefit from Share-based Compensation, Financing Activities of $0 for the 12-month period ending 2017-12-31, per its 10-K filed 2018-02-28.
Discontinued › Notes › Compensation Related Costs
us-gaap:ExcessTaxBenefitFromShareBasedCompensationFinancingActivities · last filed 2019-02-28
- Theravance Biopharma, Inc. excess tax benefit from share-based compensation, financing activities for the quarter ending 2016-12-31 was $21.00K.
- Theravance Biopharma, Inc. excess tax benefit from share-based compensation, financing activities for the quarter ending 2016-09-30 was $0.00.
- Theravance Biopharma, Inc. excess tax benefit from share-based compensation, financing activities for the quarter ending 2016-06-30 was $0.00.
- Theravance Biopharma, Inc. excess tax benefit from share-based compensation, financing activities for the quarter ending 2016-03-31 was $0.00, a 100.00% decline year-over-year.
- Theravance Biopharma, Inc. excess tax benefit from share-based compensation, financing activities for fiscal 2017 was $0.00, a 100.00% decline from fiscal 2016.
- Theravance Biopharma, Inc. excess tax benefit from share-based compensation, financing activities for fiscal 2016 was $21.00K.
- Theravance Biopharma, Inc. excess tax benefit from share-based compensation, financing activities for fiscal 2015 was -$75.00K, a 126.60% decline from fiscal 2014.
- Theravance Biopharma, Inc. excess tax benefit from share-based compensation, financing activities for fiscal 2014 was $282.00K.
| Period end | Excess Tax Benefit from Share-based Compensation, Financing Activities 3 month | Excess Tax Benefit from Share-based Compensation, Financing Activities 6 month | Excess Tax Benefit from Share-based Compensation, Financing Activities 9 month | Excess Tax Benefit from Share-based Compensation, Financing Activities 12 month |
|---|---|---|---|---|
| 2017-12-31 | $0.00 10-K · filed 2018-02-28 | |||
| 2016-12-31 | $21.00K derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-28 | $21.00K derived: sum of 2 quarters · filed 2019-02-28 | $21.00K derived: sum of 3 quarters · filed 2019-02-28 | $21.00K 10-K · filed 2019-02-28 |
| 2016-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-09 | $0.00 derived: sum of 2 quarters · filed 2016-11-09 | $0.00 10-Q · filed 2016-11-09 | -$281.00K derived: sum of 4 quarters · filed 2018-02-28 |
| 2016-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-09 | $0.00 10-Q · filed 2016-08-09 | -$281.00K derived: sum of 3 quarters · filed 2018-02-28 | -$315.00K derived: sum of 4 quarters · filed 2018-02-28 |
| 2016-03-31 | $0.00 10-Q · filed 2016-05-10 | -$281.00K derived: sum of 2 quarters · filed 2018-02-28 | -$315.00K derived: sum of 3 quarters · filed 2018-02-28 | -$466.00K derived: sum of 4 quarters · filed 2018-02-28 |
| 2015-12-31 | -$281.00K derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-28 | -$315.00K derived: sum of 2 quarters · filed 2018-02-28 | -$466.00K derived: sum of 3 quarters · filed 2018-02-28 | -$75.00K 10-K · filed 2018-02-28 |
| 2015-09-30 | -$34.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-09 | -$185.00K derived: sum of 2 quarters · filed 2016-11-09 | $206.00K 10-Q · filed 2016-11-09 | $95.00K derived: sum of 4 quarters · filed 2017-03-01 |
| 2015-06-30 | -$151.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-09 | $240.00K 10-Q · filed 2016-08-09 | $129.00K derived: sum of 3 quarters · filed 2017-03-01 | $522.00K derived: sum of 4 quarters · filed 2017-03-01 |
| 2015-03-31 | $391.00K 10-Q · filed 2016-05-10 | $280.00K derived: sum of 2 quarters · filed 2017-03-01 | $673.00K derived: sum of 3 quarters · filed 2017-03-01 | $673.00K derived: sum of 4 quarters · filed 2017-03-01 |
| 2014-12-31 | -$111.00K derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-01 | $282.00K derived: sum of 2 quarters · filed 2017-03-01 | $282.00K derived: sum of 3 quarters · filed 2017-03-01 | $282.00K 10-K · filed 2017-03-01 |
| 2014-09-30 | $393.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2015-11-12 | $393.00K derived: sum of 2 quarters · filed 2015-11-12 | $393.00K 10-Q · filed 2015-11-12 | $393.00K derived: sum of 4 quarters · filed 2015-11-12 |
| 2014-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2015-08-13 | $0.00 10-Q · filed 2015-08-13 | $0.00 derived: sum of 3 quarters · filed 2015-08-13 | |
| 2014-03-31 | $0.00 10-Q · filed 2015-05-13 | $0.00 derived: sum of 2 quarters · filed 2015-05-13 | ||
| 2013-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2015-03-13 | $0.00 10-K · filed 2015-03-13 | ||
| 2013-09-30 | $0.00 10-Q · filed 2014-11-12 | |||
| 2012-12-31 | $0.00 10-K · filed 2015-03-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cryoport, Inc. (CYRX) | United States | $0.881B | -21.29 |
| RIGEL PHARMACEUTICALS INC (RIGL) | United States | $0.893B | 2.25 |
| Apnimed, Inc. (APMD) | United States | $0.899B | |
| ARDELYX, INC. (ARDX) | United States | $0.857B | -22.86 |
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Jade Biosciences, Inc. (JBIO) | United States | $0.936B | -9.21 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |